aTyr Pharma, Inc.ATYRNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-28.6x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -50.79% |
| Q3 2025 | 43.85% |
| Q2 2025 | 30.22% |
| Q1 2025 | -3.39% |
| Q4 2024 | -17.42% |
| Q3 2024 | 5.97% |
| Q2 2024 | 4.56% |
| Q1 2024 | 4.77% |
| Q4 2023 | 23.61% |
| Q3 2023 | 4.87% |
| Q2 2023 | 4.92% |
| Q1 2023 | -37.10% |
| Q4 2022 | 51.11% |
| Q3 2022 | 8.01% |
| Q2 2022 | 2.69% |
| Q1 2022 | 49.39% |
| Q4 2021 | 15.90% |
| Q3 2021 | -32.88% |
| Q2 2021 | 69.51% |
| Q1 2021 | -3.87% |
| Q4 2020 | 1.78% |
| Q3 2020 | 5.85% |
| Q2 2020 | 20.60% |
| Q1 2020 | 0.72% |
| Q4 2019 | -5.50% |
| Q3 2019 | 14.63% |
| Q2 2019 | -0.93% |
| Q1 2019 | -5.75% |
| Q4 2018 | -15.54% |
| Q3 2018 | -35.19% |
| Q2 2018 | 5.43% |
| Q1 2018 | 15.82% |
| Q4 2017 | -25.56% |
| Q3 2017 | -15.29% |
| Q2 2017 | -8.52% |
| Q1 2017 | 0.66% |
| Q4 2016 | -12.03% |
| Q3 2016 | -8.07% |
| Q2 2016 | -5.78% |
| Q1 2016 | -5.29% |